🏛️ Verified NIH Record • Updated 2026-06-29
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma (NCT04098081)
1911GCCC: Open Label, Phase 2 Trial of Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Maryland, Baltimore
🩺 Plain-English Summary (8th-Grade Level)
Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma
Who can join: Review the eligibility criteria below.
Location: University of Maryland Medical Center — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Maryland Medical Center — Baltimore, Maryland
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Pancreatic Cancer
- Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors — Toledo, Ohio
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies — Santa Monica, California
Explore by condition: All Advanced Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.